Download MendeleyStructure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP.
Liu, H., Zakrzewicz, D., Nosol, K., Irobalieva, R.N., Mukherjee, S., Bang-Sorensen, R., Goldmann, N., Kunz, S., Rossi, L., Kossiakoff, A.A., Urban, S., Glebe, D., Geyer, J., Locher, K.P.(2024) Nat Commun 15: 2476-2476
- PubMed: 38509088
- DOI: https://doi.org/10.1038/s41467-024-46706-w
- Primary Citation of Related Structures:
8RQF - PubMed Abstract:
Cellular entry of the hepatitis B and D viruses (HBV/HDV) requires binding of the viral surface polypeptide preS1 to the hepatobiliary transporter Na + -taurocholate co-transporting polypeptide (NTCP). This interaction can be blocked by bulevirtide (BLV, formerly Myrcludex B), a preS1 derivative and approved drug for treating HDV infection. Here, to elucidate the basis of this inhibitory function, we determined a cryo-EM structure of BLV-bound human NTCP. BLV forms two domains, a plug lodged in the bile salt transport tunnel of NTCP and a string that covers the receptor's extracellular surface. The N-terminally attached myristoyl group of BLV interacts with the lipid-exposed surface of NTCP. Our structure reveals how BLV inhibits bile salt transport, rationalizes NTCP mutations that decrease the risk of HBV/HDV infection, and provides a basis for understanding the host specificity of HBV/HDV. Our results provide opportunities for structure-guided development of inhibitors that target HBV/HDV docking to NTCP.
Organizational Affiliation:
Institute of Molecular Biology and Biophysics, ETH Zürich, Zürich, Switzerland.
